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Common variable immunodeficiency disorder (CVID) is the most common symptomatic primary
immunodeficiency in adults, characterized by B-cell abnormalities and inadequate antibody response.
CVID patients have considerable autoimmune comorbidity and we therefore hypothesized that genetic
susceptibility to CVID may overlap with autoimmune disorders. Here, in the largest genetic study
performed in CVID to date, we compare 778 CVID cases with 10,999 controls across 123,127 single-
nucleotide polymorphisms (SNPs) on the Immunochip. We identify the first non-HLA genome-wide
significant risk locus at CLEC16A (rs17806056, P¼ 2.0 109) and confirm the previously reported
human leukocyte antigen (HLA) associations on chromosome 6p21 (rs1049225, P¼4.8 10 16).
Clec16a knockdown (KD) mice showed reduced number of B cells and elevated IgM levels compared with
controls, suggesting that CLEC16A may be involved in immune regulatory pathways of relevance to
CVID. In conclusion, the CLEC16A associations in CVID represent the first robust evidence of non-HLA
associations in this immunodeficiency condition.
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C
ommon variable immunodeficiency (CVID) has a pre-
valence of B1 in 25,000 in European populations.
Recurrent bacterial respiratory tract infections constitute
the predominant clinical manifestation, but a subset of CVID
patients also develops gastrointestinal manifestations and lym-
phoid hyperplasia. In addition, various forms of autoimmune
disorders affect up to 25% of the patients, of which the most
common is autoimmune thrombocytopenia1. The immunological
hallmark of CVID is the B-cell defect with inability to produce
adequate antibody responses, but patients also show other
immunological abnormalities such as T-cell dysfunction,
monocyte/macrophage hyperactivity and signs of low-grade
systemic inflammation2.
The focus of CVID genetics over the years has largely been to
determine the presence of monogenic subtypes, leading to the
identification of familial affection of a series of immunodeficiency
genes, including CD19 (ref. 3), CD20 (ref. 4), CD81 (ref. 5),
CR2 (ref. 6), ICOS7, LRBA8, PLCG2 (ref. 9), PRKCD10 and
TNFRSF13B11. However, most of the CVID cases are sporadic
and although formal heritability estimates have not been made, a
complex model of inheritance probably accounts for the majority
of patients12. The human leukocyte antigen (HLA) haplotype
association with CVID was found earlier by tissue typing13 and a
recent genome-wide association study in CVID further supports a
complex genetic heritability in CVID, with common variants
within the HLA complex associating with disease development14.
To what extent common genetic variations outside this region
contribute to CVID susceptibility is unknown.
We hypothesize that the autoimmune comorbidity in CVID
may occur on the basis of shared genetic susceptibility. We
perform dense autoimmune risk loci genotyping on the
Immunochip in 778 CVID cases and 10,999 controls, represent-
ing the largest CVID study panel investigated for genetic risk
factors to date. We identify a novel non-HLA risk locus at
CLEC16A and replicate the previously reported HLA associations
at chromosome 6p21. In Clec16 knockdown (KD) mice, we found
a reduced proportion of B cells and elevated IgM secretion,
pointing to a role of CLEC16A in B-cell function of potential
relevance to CVID and other CLEC16A associated conditions.
Results
A novel CVID susceptibility locus harbouring CLEC16A. To
systematically assess established autoimmune risk loci for
associations in CVID, we genotyped 886 CVID cases and 11,552
controls of European ancestry from Sweden, Norway, Germany,
United Kingdom and the United States (Table 1, Supplementary
Table 1 and Supplementary Fig. 1), using the Immunochip,
a targeted genotyping array with dense single-nucleotide poly-
morphism (SNP) coverage across 186 known disease loci from 12
immune-mediated diseases15. Following standard quality-control
(QC) measures, a total of 123,127 SNPs with a minor allele
frequency 41% from 778 cases and 10,999 controls remained
available for analysis. Association testing was performed using
logistic regressions with the first three principal components as
covariates to adjust for population structure (residual genomic
inflation factor l¼ 1.04) (Supplementary Figs 2 and 3).
On chromosome 16p13.13, we detected 22 genome-wide
significant (Po5 10 8) SNPs spanning the CLEC16A locus
in our logistic regression analysis. The most strongly associated
SNP (rs17806056, P¼ 2.0 10 9) was located in intron 19 of
CLEC16A (Table 2 and Fig. 1a,b). Fifteen additional imputed
SNPs also showed genome-wide significance (Supplementary
Table 2). Conditioning on SNP rs17806056, significant associa-
tions of other CLEC16A SNPs were ablated, suggesting that the
SNP is representative of a single association signal at CLEC16A.
CLEC16A encodes a protein belonging to the C-type lectin-like
domain family and is expressed in dendritic cells, natural killer
cells and B cells16,17. Stratified analysis also suggested that
CLEC16A variants may correlate with several clinical subtypes
and immunological phenotypes in CVID (for example, lymphoid
hyperplasia) and not just the autoimmune subtype
(Supplementary Table 3), although none of these associations
were robust at the genome-wide significance level.
We conducted quantitative real-time PCR on blood from
CVID cases, to investigate whether there is any correlation
between CLEC16A expression and the rs17806056 genotype.
Statistically significant higher level of CLEC16A messenger RNA
was detected in the AA group, which carries two copies of the
minor allele, compared with the TT group (Fig. 1c). We did not
find any significant difference in mRNA levels of the neighbour-
ing SOCS1 or DEXI genes according to rs17806056 genotype
status (Supplementary Fig. 4). We further assessed annotations
from the ENCODE18 project for all CVID-associated SNPs within
the 16p13.13 region (Supplementary Table 4). Of note, several of
the CVID-associated SNPs (rs36110069, rs35300161, rs2867880,
rs7203459 and rs34972832) are predicted to affect binding sites
for the GATA2 transcription factor where binding to SNP
rs34972832 and neighbouring sequences is detected in the human
K562 leukemia cell line18. GATA2 is also involved in different
adult immunodeficiency state (monoMAC syndrome)19. Further
studies are warranted to explore the relevance of these
observations in vivo.
Clec16 KD affects murine B cells. Whereas CLEC16A is highly
expressed in human B cells, a role of CLEC16A in these cells has
not been established. Given the paramount importance of B-cell
defects in CVID development, we explored the biological impli-
cations of Clec16a KD in murine B cells isolated from splenocytes.
We detected a 54.4% (±8.4%) reduction of the total number of
CD19þ B cells in the splenocyte population after induction
of Clec16a KD using tamoxifen, when compared with non-
tamoxifen-treated littermates (control group; P¼ 6.25 10 6 in
two-sided T-test). In particular, the fraction of CD19þ B cells in
splenocytes is reduced (17.4±5.0%, P¼ 2.45 10 3 in two-
sided T-test) (Fig. 2a and Supplementary Table 5). We did not
detect significant differences in the fraction of CD27þ cells or for
B-cell proliferation assaying (MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide)). However, B cells from
Clec16a-deficient mice exhibited an altered immunoglobulin (Ig)
profile as compared with control mice with increased levels of
IgM (P¼ 0.003 in two-sided T-test), but no changes in serum
levels of IgG and IgA (Fig. 2b). In sum, the supplementary murine
Clec16a data suggest an impact of CLEC16A on B-cell function.
Candidate gene association statistics. In addition to the
genome-wide significant CLEC16A locus, we also found six loci
exhibiting suggestive evidence for association (5 10 8o
P-value o5 10 5; Supplementary Fig. 5 and Supplementary
Table 6). Although replication in future study panels is required
Table 1 | Overview of number of included patient and control
panels before quality control, according to geography.
Cases, n Controls, n Total, n
Sweden 93 2096 2189
Norway 112 1405 1517
USA/UK 330 1402 1732
Germany 351 6649 7000
Total 886 11552 12438
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for formally establishing these loci (FCRLA, EOMES, TNIP1,
TNFAIP3, TNFSF11 and PTPN2) in CVID, prior probability for
genuine association is enhanced by findings in other immune-
mediated diseases (Supplementary Table 6). Furthermore, SNPs
at four genes previously suggested to be involved in familial
CVID subtypes, CR2, ICOS, MSH5 and TNFRSF13B, showed
nominally significance association (Po0.05) in the present
analysis (Supplementary Table 7).
HLA-DQB1 associations. In line with previous studies14 we
detected strong associations with SNPs within the HLA complex
on chromosome 6p21, peaking at rs1049225 in the 30
untranslated region of HLA-DQB1 (P¼ 4.8 10 16; Table 2,
Fig. 1a and Supplementary Fig. 6). By stepwise conditional logistic
regressions, we found that the association signal consists of
multiple independent effects (Supplementary Table 8 and
Supplementary Fig. 7). We imputed classical HLA-A, HLA-C,
Table 2 | Genome-wide significant (Po5 108) associations detected by logistic regression analysis of 778 cases with CVID
and 10,999 population controls.
SNP* Chr. Position (hg19) A1/A2 MAF cases/controls OR (95% CI) P-value Candidate gene Additional SNPsw
rs1049225 6p21 32,627,747 A/G 0.16/0.26 0.56 (0.49, 0.64) 4.8 10 16 HLA-DQB1 154
rs17806056 16p13.13 11,192,499 A/T 0.18/0.23 0.66 (0.57, 0.75) 2.0 109 CLEC16A 21
A1, minor allele; A2, major allele; Chr, chromosome; CI, confidence interval; CVID, common variable immunodeficiency disorder; MAF, minor allele frequency; OR, odds ratio; SNP, single-nucleotide
polymorphism.
*Most associated SNP from each locus.
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Figure 1 | The association statistics for CVID and the relative expression level of CLEC16A in different genotype groups. (a) A Manhattan plot of the
Immunochip association statistics illustrating CVID susceptibility loci. SNP locations are plotted on the x axis according to their chromosomal position. The
negative log10 of P-values per SNP derived from the association analysis are plotted on the y axis. The horizontal red line represents the genome-wide
significance threshold of P¼ 5 10 8. (b) The regional association plot48 for the CLEC16A locus. The most associated SNP (rs17806056) is indicated by
the purple dot, while the colours of the remaining SNPs indicate the LD with the index SNP, as shown in the colour legend. The light blue line shows
the recombination rates (HapMap project49) and genomic positions are from genome build hg19. The plot was generated using software LocusZoom48.
(c) The relative expression level of CLEC16A compared between CVID cases of different genotypes at rs17806056. The mRNA level of CLEC16A was
assessed by quantitative reverse transcriptase–PCR and normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) control. The relative fold
change (y axis) was plotted against the genotype for SNP rs17806056 (x axis). Each blue dot represents the average value of three measurements from
each individual sample and the black line through the dots represents the mean level among each genotype group. The number of samples in each group is
n¼4 AA, n¼ 7 TA and n¼ 11 TT. P-value was determined by two-sided T-test.
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HLA-B, HLA-DRB1, HLA-DQB1, HLA-DQA and HLA-DPB1
alleles (Supplementary Table 9), revealing HLA-DQB1
associations with HLA-DQB1*02:01 and *05:03(risk alleles), as
well as HLA-DQB1*06:02 and DQB1*06:03 (protective alleles).
Further studies involving direct sequencing of all HLA class I and
II loci and determination of their protein structure and peptide
binding profiles are required to further explore the link between
these HLA haplotypes and CVID development. It is noteworthy
that for the present report, we found no statistical evidence for
interaction between CLEC16A and the HLA-associated risk to
CVID (Supplementary Table 10).
Autoimmune disease associations at the CLEC16A locus.
Genome-wide association studies have detected CLEC16A
associations in multiple phenotypes ranging from prototypical
autoimmune disorders (for example, type 1 diabetes20 and
primary biliary cirrhosis21) via immune-mediated conditions
driven by exogenous antigens (for example, celiac disease22 and
allergy23) to suggestive associations (P¼ 1.8 10 7) observed in
selective IgA deficiency24. The majority of significant SNPs from
these studies are trans-ethnic, localize to the same linkage
disequilibrium (LD) block and are in high to moderate LD with
the most strongly associated SNP within CLEC16A in the current
study (rs17806056; Supplementary Table 11).
Discussion
The present study has demonstrated a potential role of CLEC16A
in the pathogenesis of CVID by strong genetic associations and its
involvement in murine B-cell function.
Because of the prominent CLEC16A SNP associations in a
variety of auto-immune diseases, several studies have been carried
out to examine the biological function of CLEC16A. Its
Drosophila homologue Ema has been found to localize to the
endosomal and Golgi membranes25,26. Ema mutants show defects
in lysosomal degradation and protein trafficking25. It is also
essential for autophagosomal growth and autophagy processes26,
which are of major importance for proper immune regulation,
including regulation of inflammasome activation. CLEC16A is
evolutionarily conserved and may rescue the Drosophila Ema
mutant phenotypes25,26. Human CLEC16A has been reported to
be abundantly expressed in dendritic cells, natural killer cells and
B cells16,17. Zouk et al.27 demonstrated, by using a human
erythromyeloblastoid leukemia cell line, K562 cells, and human
lymphoblastoid cell lines, that CLEC16A is localized with an
endoplasmic reticulum marker, and that KD of CLEC16A did not
affect T-cell co-stimulation. Recent murine data indicated that
Clec16a is localized at endosomal membrane and forms a protein
complex with Nrdp1, which is an E3 ubiquitin–protein ligase28.
Clec16a may thus regulate mitophagy through the Nrdp1/Parkin
pathway28. Adding to this existing knowledge, the present study
has shown that CLEC16A may also be involved in B-cell function.
Although we could not reproduce the complete CVID phenotype
in Clec16a KD B cells, findings strongly suggest that CLEC16A, in
combination with other dysregulated pathways, may contribute to
the B-cell dysfunction observed in these patients.
The relationship of CLEC16A expression and its genotype
status has been investigated. We have previously shown that
CLEC16A is differentially expressed based on the risk allele,
reported with the protective minor allele showing a higher
expression than the risk allele20, and a similar observation was
made in the present study. The correlation is further complicated
by the existence of three CLEC16A isoforms, which could lead to
isoform-specific correlations. Examining the relative expression
level of the long isoforms versus short isoform, a correlation with
multiple sclerosis-associated SNP rs12708716 genotype status has
been observed in human thymic tissues. However, no association
was found when it was examined in whole blood29. Therefore, the
effect of SNP genotype status on CLEC16A expression could be
both isoform specific and cell-type/tissue-type dependent30.
Furthermore, the sample size in each study is small and may be
underpowered to detect a correlation. At this stage, although
CLEC16A is a promising candidate gene to function in the
pathogenesis of CVID as demonstrated in our study, we could not
fully exclude the possibility that CVID-associated SNPs in
CLEC16A introns are tagging other proximal genes, although
we find this is unlikely.
The identification of CLEC16A as a significant CVID risk locus
reflects the notion that most genetic risk loci for immune-related
diseases are pleiotropic. Significant overlap of risk loci between
autoimmune disease and immune deficiency has also been found
for those of rheumatoid arthritis31. The biological explanation of
the overlap probably differs from locus to locus, but the overall
interpretation is that of an imperfect relationship between clinical
disease phenotyping and genetically determined pathophysiology.
Importantly, the finding of CLEC16A associations in both
autoimmunity, allergy and, as given by the present study, an
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Figure 2 | The effect of inducible Clec16a KD in murine B cells. (a) Percentage of B cells (CD19þ cells) from splenocytes of inducible Clec16a KD
mice after tamoxifen treatment and the littermates treated with oil as a control in two independent experiments by fluorescence-activated cell sorting
analysis. Data from the two experiments were combined. Black and red dots represent data from control (Cntr) and Clec16a KD mice, respectively.
The black lines through the dots represent the mean level among the ten control mice and nine Clec16a KD mice, respectively. Two-sided T-test was used to
compare the percentage of CD19þ cells between Clec16A KD mice and control littermates. (b) Ig production from the supernatants of B cells, purified from
Clec16A KD mice splenocytes, cultured with anti-mouse CD40 (100 ng ml 1) for 6 days. Data from two independent experiments were combined. Data are
mean±s.d. of seven mice in each group. Two-sided T-test was used to compare the level of each Ig subtype produced from Clec16A KD and control
littermates.
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response to certain capsulated bacteria, is particularly interesting,
as the mechanisms leading to persistent immune activation and
autoimmunity in CVID is not clear. Our findings may suggest
that altered function of CLEC16A could be ‘the missing link’
between immunodeficiency and immune action in CVID. The
current identification of novel, highly robust CLEC16A
associations in CVID raises conceptually novel opportunities
for exploring mechanisms underlying the autoimmune co-
morbidity and the chronic inflammation observed in CVID.
Hypothetically, the CLEC16A-associated aspects of adult
immunodeficiency states may reveal novel concepts for the
basis of immune activation in autoimmunity.
In conclusion, we have identified the first genome-wide
significant non-HLA CVID risk locus at CLEC16A in the largest
genetic study performed in this disease to date. CLEC16A has
previously been linked to autoimmune disorders and the fact that
Clec16a-deficient mice showed decreased number of B cells
suggests that CLEC16A could represent a link between auto-
immunity and immunodeficiency in CVID.
Methods
Study subjects description. Study subjects were recruited from five countries:
Sweden, Norway, the United States, the United Kingdom and Germany (Table 1
and Supplementary Table 1) The diagnosis of CVID was defined as decreased
serum levels (42 s.d.) of IgG, IgA and/or IgM, and exclusion of other forms
of hypogammaglobulinemia according to the World Health Organization
expert group on primary immunodeficiency and the International Union of
Immunological Societies32,33. Controls were recruited from blood donors or
population-based studies.
The Swedish CVID cases (n¼ 93) were recruited at the Department of
Laboratory Medicine, Division of Clinical Immunology and Transfusion Medicine,
Karolinska University Hospital, Huddinge, Stockholm. The Swedish controls
(n¼ 2,096) were part of a population based case–control study named
Epidemiological Investigation of Rheumatoid Arthritis34.
The CVID patients in the Norwegian panel (n¼ 112) were recruited from the
Section of Clinical Immunology and Infectious Diseases at Oslo University
Hospital Rikshospitalet, Oslo, Norway. DNA samples from healthy Norwegian
controls (n¼ 1,405) were selected from the Norwegian Bone Marrow Donor
Registry and the North-Trøndelag Health Study (HUNT).
The CVID patients in the United States/United Kingdom panel (n¼ 330) were
recruited from four locations: the Immunodeficiency Clinic at Mount Sinai Medical
Center, New York, NY, the Division of Allergy, Immunology and Rheumatology,
All Children’s Hospital, St Petersburg, FL, the Division of Allergy and Immunology
at The Children’s Hospital of Philadelphia, PA, and the Department of Clinical
Immunology in the Nuffield Department of Medicine, Oxford Radcliffe Hospital,
UK. All the US/UK cases were genotyped at the Center for Applied Genomics,
Children’s Hospital of Philadelphia, PA.
The US controls (n¼ 1402) were recruited at the University of Michigan and
genotyped at the Institute of Clinical Molecular Biology, Christian-Albrechts-
University of Kiel (as part of the PAGE Immunochip data set35).
The German CVID cases (n¼ 351) were recruited at the Center for Chronic
Immunodeficiency, University Hospital of Freiburg, and at the Clinic for
Immunology and Rheumatology, Hannover Medical School, Hannover. DNA from
2,696 German healthy controls was obtained through the Northern German biobank
PopGen36 (http://www.popgen.de) and the University Hospital
Schleswig-Holstein. Genotyping of these 2,696 controls was performed at the
Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel.
One thousand nine hundred and twenty-four German controls were part of an
independent population-based sample from the general population living in the
region of Augsburg (Cooperative Health Research in the Region of Augsburg),
southern Germany37, and were genotyped at the Helmholtz Center in Munich.
One thousand and five hundred German controls were recruited from the
population-based epidemiological Heinz-Nixdorf Recall study and genotyped at the
Life and Brain Center at the University Clinic Bonn. Three hundred and fourteen
individuals were of south German ancestry and were part of the control population
Munich recruited from the Bavarian Red Cross and 215 individuals were recruited
from the Charité-Univeristätsmedizin Berlin. These samples were genotyped at the
University of Pittsburgh Genomics and Proteomics Core Laboratories.
Respective regional ethics committees are listed for all sites that provided patients
and/or controls to the study, all of which were approved: The regional ethical review
board in Stockholm, The Regional Committees for Medical and Health Research
Ethics South East (Norway) for Norwegian patients and The Regional Committee for
Medical and Health Research Ethics Central (Norway) for the HUNT controls,
Children’s Hospital of Philadelphia Institutional Review Board, Mount Sinai School
of Medicine Institutional Review Board, University of Oxford Institutional Review
Board, University of South Florida Institutional Review Board, the University of
Michigan Medical School Institutional Review Board, Ethikkommission der
Universitätsklinik Freiburg, Ethik-Kommission der Medizinische Hochschule
Hannover, Ethik-Kommission der Medizinischen Fakultät der Christian-Albrechts-
Universität zu Kiel, Ethics committee of the University Hospital S.-H., Campus Kiel
(Kiel University), Ethics committee of the Faculty of Medicine, Ludwig-Maximilians-
University Munich, Germany, Ethikkommission der Bayerischen Landesärzte-
kammer for the KORA controls, Ethikkommission der Universität Duisburg-Essen
for HNR controls, Ethikkommission der Charité-Universitätsmedizin Berlin for
Berlin Charite controls. Written informed consent for blood sample collection,
processing and genotyping were obtained by all participants.
Immunochip genotyping. DNA samples were genotyped using the Immunochip,
an Illumina iSelect HD custom genotyping array. This BeadChip was developed for
highly multiplexed SNP genotyping and the SNP content of this array was mainly
based on findings in ankylosing spondylitis, autoimmune thyroiditis, Crohn’s
disease, celiac disease, IgA deficiency, multiple sclerosis, primary biliary cirrhosis,
psoriasis, rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes and
ulcerative colitis. Genotyping was performed according to Illumina protocols, with
4 ml of genomic DNA samples at 50 ng ml 1, aliquoted to the corresponding wells
of 96-well plates. The NCBI build 36 (hg19) map was used (Illumina manifest file
Immuno_BeadChip_11419691_B.bpm) and normalized probe intensities were
extracted for all samples passing standard laboratory QC thresholds. Genotype
calling was performed with Illumina’s GenomeStudio data analysis software, the
GenomeStudio GenTrain 2.0 algorithm and the cluster file generated by Trynka
et al.38 (based on the clustering of 2,000 UK samples and subsequent manual
re-adjustment of cluster positions).
All CVID cases from Norway, Sweden and Germany were genotyped at the
Institute of Clinical Molecular Biology in Kiel, Germany. The US/UK cases were
genotyped at the Center for Applied Genomics, the Children’s Hospital of
Philadelphia, USA.
Quality control. Sample QC measures included sample call rate, overall hetero-
zygosity, relatedness testing and other metrics: samples with a SNP call rateo98%
(n¼ 309) as well as heterozygosity outliers (n¼ 15), defined as beyond 5 s.d. of the
mean, were excluded from analysis. Duplicate samples (n¼ 37) and cryptically
related samples (PI_HAT Z0.1875; n¼ 199) were identified through identity-by-
state calculations with PLINK39. For each pair of duplicate or related samples, the
sample with the highest SNP call rate was kept in the data set. Finally, removal of
population outliers (non-Caucasians; n¼ 101) was performed based on principal
component analysis of population heterogeneity, which is described below in detail
as ‘Principal component analysis’.
In the SNP-based QC SNPs with a call rate o98%, with a minor allele
frequency o1% and markers that deviated from Hardy–Weinberg equilibrium test
(P-valueo10 5) in the controls or SNPs with significant different genotyping rate
between cases and controls (Po1 10 5 in Fisher’s exact test) were removed.
Applying the QC procedures described above resulted in 778 CVID cases and
10,999 controls available for association analysis.
Principal component analysis. Principal component analysis was conducted once
to identify ethnic outliers and once again to generate covariates to control for
population stratification. For the first analysis, we used HapMap samples as a
reference set and 13,001 uncorrelated SNPs that passed the above QC criteria and
are present in both our Immunochip data set and HapMap data set, which were LD
pruned such that no pair of SNPs had r240.2 and excluding problematic GC/AT
SNPs and X- and Y-chromosomes. PLINK was used for LD pruning and exclusion
of SNPs. All samples that did not cluster with the European samples were excluded.
After removal of ethnicity outliers, second principal component analysis was
performed within the remaining Immunochip samples to resolve within-Europe
relationships. No population stratification in the remaining samples was observed.
Principal component analyses were performed using EIGENSTRAT40 version 4.0.
Association analysis. For case–control association testing, logistic regression with
PLINK was performed using the first three principal components from the
EIGENSTRAT analysis as covariates, which are sufficient to control for potential
population stratification as determined by the genomic inflation factor. Sub-
phenotype analysis was similarly conducted via logistic regression. Step-wise
conditional association analysis was performed by including the most strongly
associated SNP in the previous step as a covariate. Post-hoc power assessment
showed over 99% power to detect genome-wide significant association at the HLA
SNP rs1049225 (odds ratio (OR)E1.75) with 778 cases and 14-fold number of
controls, and B83% power for the CLEC16A SNP, rs17806056 (ORE1.5;
Supplementary Fig. 8).
SNP imputation and association testing. For the CLEC16A locus on chromo-
some 16, haplotype pre-phasing was performed using SHAPEIT41,42 version 2.
Genotype imputation was conducted using the IMPUTE2 (refs 43,44) package. The
1000 Genomes Phase I integrated variant set was used as reference panel and data
were downloaded from the IMPUTE2 website (http://mathgen.stats.ox.ac.uk/
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impute/data _download_1000G_phase1_integrated.html). After imputation, the
SNPTEST v2 package was used to perform association analysis on the imputed
genotypes. Missing data likelihood score test, implemented in SNPTEST43 v2, was
employed to take imputation uncertainty into account. The first three principal
components were included in the model as covariates. SNPs with low quality,
with info scoreo0.8 or with Hardy–Weinberg equilibrium test P-valueo10 6
were excluded.
Power analysis. Power analysis was conducted using software Power for
Genetic Association45, with the following settings: Genetic Model¼Co-dominant
(1 df) SNP analysis; R2¼ 1; Disease prevalence¼ 0.00004; Marker allele
frequency¼Disease allele frequency¼ 0.75; Effective degree of freedom¼ 123,127;
a¼ 0.05 and control to case ratio¼ 14. Relative risk was set at 1.5, 1.75 and 2,
to generate three power curves.
Animals. All animal studies were approved by the Institutional Animal Care and
Use Committee of the Children’s Hospital of Philadelphia. To generate Clec16aloxP
mice, a 15.3-kb DNA fragment containing Clec16a exons 2–4 and flanking intronic
sequence was retrieved from C57BL/6 mouse genomic DNA and subcloned into
plasmid FLSniper (Ozgene) that contains an FRT-flanked PGK-driven Neomycin
cassette for negative selection. One loxP site was inserted upstream of exon 3, while
a second loxP site was placed downstream of exon 3. The linearized targeting
vector was electroporated into B6 ES cells and clones that survived selection were
screened for homologous recombination by Southern blot analysis. Targeted clones
were injected into C57BL/6-derived blastocysts that were then transferred to
pseudopregnant females. Male offspring were mated to C57BL/6 females and ES
cell-derived offspring were identified by PCR-based genotyping. Mice harbouring
the targeted insertion of the two loxP sites in the Clec16a gene locus were
then crossed to the Flpo Deleter line (mouse Strain: 129S4/SvJae-Gt(ROSA)26-
Sortm2(FLP*)Sor/J; The Jackson Laboratory) to achieve deletion of the FRT-
flanked Neomycin cassette. Clec16aloxP mice were mated to UBC-Cre-ER-LBD-tg
mice (inducible cre recombinase driven by the human ubiquitin C promoter),
to generate UBC-Cre-Clec16aloxP mice.
To generate experimental groups, UBC-Cre-Clec16aloxP male mice were treated
with tamoxifen (for Clec16a KD) or oil (control group). Tamoxifen (MP
Biomedical) was prepared at a concentration of 20 mg ml 1 in 10% ethanol and
90% corn oil (Sigma). Four-week-old male mice received 1 mg of tamoxifen at 24-h
intervals for 5 consecutive days by gavage. Control group of mice were receiving an
equal volume of corn oil alone. After tamoxifen treatment was finished, mice were
aged an additional 2 weeks before evaluation.
Quantitative real-time PCR. The total RNA was extracted from human blood
using Trizol (Ambion, Life Technologies) and converted to complementary DNA
with High Capacity RNA-to-cDNA Kit, following the manufacturer’s protocols
(Applied Biosystems). Briefly, 1 ml of Trizol was mixed to 50 ml of whole blood,
followed by 200ml of chloroform. The mixture was centrifuged at 12,000g for
15 min at 4 C. The upper aqueous phase (containing RNA) was purified with
RNAeasy kit (Qiagen). Quality of RNA was assessed by Agilent Bioanalyzer.
Fluorescence-based real-time PCR was performed in 10 ml of reaction mixture,
using cDNA, TaqMan Universal Master Mix and 20 FAM-MGB TaqMan assays
(Applied Biosystems): Hs00322376_m1 (CLEC16A), Hs00360234_m1 (DEXI),
Hs00705164_s1 (SOCS1) and Hs02758991_g1 (glyceraldehyde 3-phosphate
dehydrogenase). Relative gene expression was normalized to glyceraldehyde
3-phosphate dehydrogenase. All PCR runs were performed on ViiA 7 Real Time
PCR System using ViiA7 RUO software v1.2.2 (Life Technologies).
Flow cytometry. Single-cell suspensions from murine spleens (106 cell per test)
were stained with fluorochrome-conjugated monoclonal antibodies in a single tube
containing anti-mouse CD19-Alexa Fluor 647 (BioLegend 115522), IgD-Alexa
Fluor 488 (BioLegend, 405718), IgM-Brilliant Violet 421 (BioLegend 406517) and
CD27-PE (BioLegend 124209) antibodies (1:20 dilution) for 30 min at 4 C.
Cell-associated fluorescence was assessed with an LSR-II flow cytometer and
analysed using FACSDiva software (both BD). Two independent experiments were
conducted, comparing the percentage of CD19þ cells (B cells) from splenocytes
between inducible Clec16a KD mice after tamoxifen treatment and the littermates
treated with oil as a control. Data were combined together and B-cell percentage
was compared via two-sided T-test.
Naı̈ve B-cell proliferation and Ig synthesis. Naive B cells from splenic cell
suspensions were negatively selected using EasySep Mouse B-cell Enrichment Kit,
following the manufacturer’s instructions (StemCell). Purified B cells were
suspended in RPMI containing 10% fetal bovine serum, L-glutamine and 50 mM
b-mercaptoethanol (complete medium). For Ig synthesis, naive B cells (106 cell
per ml) were cultured in complete medium alone, with lipopolysaccharide
(20 mg ml 1; Sigma-Aldrich) or with anti-mouse CD40 (100 ng ml 1;
Pharmingen). Supernatants were collected after 6 days and analysed for various
Ig production by Pierce ELISA Mouse mAb Isotyping Kit, following the
manufacturer’s instructions (Thermo Scientific). Proliferation was measured using
Cell Proliferation Kit I (MTT), following the manufacturer’s instructions (Roche).
For proliferation, aliquots of 105 B cell in 100 ml of complete medium alone,
or in the presence of lipopolysaccharide (20 mg ml 1) or anti-mouse CD40
(100 ng ml 1), were cultured in a 96-well flat-bottom plate for 48 h, then the MTT
labelling reagent was added to a final concentration 0.5 mg ml 1 followed by
overnight incubation with the solubilization solution. Proliferation was assessed by
measuring the absorbance using a microplate (ELISA) reader.
HLA analyses. Conditional analysis did not demonstrate evidence for independent
association signals at the HLA-DQBI locus.
Imputation of classical alleles at HLA class I and II loci was performed using
SNP2HLA with a reference panel consisting of 5,225 unrelated individuals
collected by the Type 1 Diabetes Genetics Consortium46.
To further explore the HLA class I and HLA class II associations with CVID,
HLA allele frequencies between cases and controls at a two-digit level were
analysed. The effect size of the association was measured with OR and the
confidence interval for the OR was calculated directly from the 2 2 table using the
Woolf’s formula47.
Western blot analysis. For western blot analysis, lysis of splenocytes was per-
formed with NP40 lysis buffer (Invitrogen). Proteins were separated on 4–12%
NuPAGE Bis-Tris gels in MOPS SDS running buffer and transferred overnight
onto nitrocellulose membranes (Invitrogen). The membranes were blocked in 3%
BSA and cut in half. The upper half of the membranes was incubated with rabbit
anti-CLEC16A polyclonal antibody (Abgent, AP6983c) at 1:1,000 dilution and the
lower half of the membranes was probed with mouse anti-b-Actin monoclonal
antibody (Abcam, ab6276) at 1:1,000 dilution. The membranes were washed,
incubated with corresponding secondary antibody for 1 h and washed again; bound
antibody was detected with WesternBright ECL chemiluminescence detection
system (Advansta). Band intensities were measured using Image J software (NIH
Shareware). Representative western blot for Clec16a in splenocytes of Clec16a KD
and control mice is shown in Supplementary Fig. 9.
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